{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:32:35Z","timestamp":1759411955346},"reference-count":45,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.vaccine.2015.03.071","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T18:54:18Z","timestamp":1428260058000},"page":"2470-2476","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents"],"prefix":"10.1016","volume":"33","author":[{"suffix":"Jr., M.D.","given":"James C.","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Ph.D.","given":"Yonghong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Ph.D.","given":"Conrad P.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Ph.D.","given":"Thomas M.","family":"Dreier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"M.S.","given":"Cabrini","family":"Vianney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Ph.D.","given":"Eric M.","family":"Espeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.03.071_bib0230","series-title":"High threat agents (category A)","author":"Official website of the Department of Homeland Security","year":"2014"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.071_bib0235","doi-asserted-by":"crossref","DOI":"10.3201\/eid1404.070969","article-title":"Conference report on public health and clinical guidelines for anthrax","volume":"14","author":"Stern","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0240","series-title":"BioThrax\u00ae package insert","author":"BioThrax\u00ae","year":"2014"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0245","unstructured":"FDA. Vaccines, Blood and Biologics. May 17, 2012 Approval Letter - BioThrax. \u3008http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm304758.htm\u3009 (accessed June 6, 2014)."},{"key":"10.1016\/j.vaccine.2015.03.071_bib0250","doi-asserted-by":"crossref","first-page":"25077","DOI":"10.1074\/jbc.M109.022061","article-title":"Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies","volume":"284","author":"Abboud","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0255","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1574-695X.2006.00114.x","article-title":"Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen","volume":"47","author":"Gubbins","year":"2006","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0260","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CVI.13.2.208-213.2006","article-title":"Neutralizing antibodies and persistence of immunity following anthrax vaccination","volume":"13","author":"Hanson","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0265","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/IAI.01254-08","article-title":"Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed","volume":"77","author":"Reason","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0270","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Sawada-Hirai","year":"2004","journal-title":"J Immune Based Ther Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CVI.00321-07","article-title":"Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor","volume":"15","author":"Taft","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0280","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/IAI.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2015.03.071_bib0285","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/0022-1317-51-10-821","article-title":"In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody","volume":"51","author":"Welkos","year":"2002","journal-title":"J Med Microbiol"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2015.03.071_bib0290","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"issue":"RR-6","key":"10.1016\/j.vaccine.2015.03.071_bib0295","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0300","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.282.22.2104","article-title":"Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax","volume":"282","author":"Friedlander","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0305","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8561(03)00093-6","article-title":"Anthrax vaccine: a review","volume":"23","author":"Grabenstein","year":"2003","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0310","series-title":"The anthrax vaccine: is it safe?. Does it work?","author":"Joellenbeck","year":"2002"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0315","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0320","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0264-410X(02)00172-X","article-title":"Aluminum-containing vaccine associated adverse events: role of route of administration and gender","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0325","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0330","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0264-410X(02)00058-0","article-title":"Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.071_bib0335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.jom.0000058345.05741.6b","article-title":"Analysis of adverse events after anthrax immunization in US Army medical personnel","volume":"45","author":"Wasserman","year":"2003","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0340","author":"Bradley","year":"2014","journal-title":"Pediatric anthrax clinical management"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0345","series-title":"Challenges in the use of anthrax vaccine adsorbed (AVA) in the pediatric population as a component of post-exposure prophylaxis (PEP)","author":"A report of the National Biodefense Science Board","year":"2011"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0350","series-title":"Safeguarding children. Pediatric medical countermeasure research","author":"Presidential Commission for the Study of Bioethical Issues","year":"2014"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0355","unstructured":"U.S. Department of Health and Human Services. Code of federal regulations. Additional protection for children involved as subjects in research. http:\/\/www.hhs.gov\/ohrp\/human subjects\/guidance\/45cfr46.html (Accessed 6.6.14)."},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.071_bib0360","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2013.10.039","article-title":"Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial","volume":"32","author":"Wright","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.071_bib0365","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"Apr (19)","key":"10.1016\/j.vaccine.2015.03.071_bib0370","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.vaccine.2014.01.073","article-title":"Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax\u00ae regimen for post-exposure prophylaxis in healthy adults","volume":"32","author":"Hopkins","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0375","unstructured":"Clinical Trials.gov. Ciprofloxacin c0-Adminstration study. Sponsor Emergent Biosolutions. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01753115?term=emergent+anthrax&rank=5 (Accessed 6.6.14)."},{"key":"10.1016\/j.vaccine.2015.03.071_bib0380","series-title":"What is a serious adverse event?","author":"U.S. Food and Drug Administration","year":"2014"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2015.03.071_bib0385","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1016\/j.vaccine.2015.03.071_bib0390","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CDLI.11.5.919-923.2004","article-title":"Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum","volume":"11","author":"Semenova","year":"2004","journal-title":"Clinic Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2015.03.071_bib0395","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Participating laboratories. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of function antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2015.03.071_bib0400","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4161\/hv.8476","article-title":"Sex differences in injection site reactions with human vaccines","volume":"5","author":"Cook","year":"2009","journal-title":"Hum Vaccine"},{"issue":"May (Suppl. 3)","key":"10.1016\/j.vaccine.2015.03.071_bib0405","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0264-410X(02)00163-9","article-title":"Workshop summary, aluminum in vaccines","volume":"20","author":"Eickhoff","year":"2002","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2015.03.071_bib0410","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/jama.2014.3633","article-title":"Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial","volume":"311","author":"Munoz","year":"2014","journal-title":"JAMA"},{"issue":"Oct (46)","key":"10.1016\/j.vaccine.2015.03.071_bib0415","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.vaccine.2011.07.068","article-title":"Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4\u20135 years after a previous dose","volume":"29","author":"Halperin","year":"2011","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2015.03.071_bib0420","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2014.03.063","article-title":"Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine","volume":"32","author":"Daley","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.03.071_bib0425","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/INF.0b013e3181ea5866","article-title":"Reactogenicity of tetanus, Diphtheria. 5-Component acellular pertussis vaccine administered as a sixth consecutive acellular pertussis vaccine dose to adolescents","volume":"29","author":"Liese","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.03.071_bib0430","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1016\/S0264-410X(03)00496-1","article-title":"Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTap) administered as a booster to 4\u20136 year-old children primed with four doses of whole-cell pertussis vaccine","volume":"21","author":"Kosuwon","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.071_bib0435","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2013.10.039","article-title":"Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial","volume":"32","author":"Wright","year":"2014","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2015.03.071_bib0440","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1016\/j.vaccine.2012.07.067","article-title":"Disability among US army veterans vaccinated against anthrax","volume":"30","author":"Sulsky","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.071_bib0445","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1047-2797(03)00124-8","article-title":"Anthrax vaccination and self-reported symptoms, functional status, and medical conditions in the National Health Survey of Gulf War Era Veterans and Their Families","volume":"14","author":"Mahan","year":"2004","journal-title":"Ann Epidemiol"},{"issue":"28","key":"10.1016\/j.vaccine.2015.03.071_bib0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vaccine.2014.04.025","volume":"32","author":"Pondo","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15003904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T13:28:29Z","timestamp":1598880509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15003904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":45,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0264410X15003904"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}